Acadia Pharmaceuticals vs Insmed
ACAD and INSM side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ACAD and INSM compare
Insmed is the larger company, worth 8.2 times as much as Acadia Pharmaceuticals ($26.6B against $3.2B).
Insmed grew revenue faster over the last twelve months (240% versus 14.8% for Acadia Pharmaceuticals).
Acadia Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of 30.1% compared with −39.9% at Insmed.
Acadia Pharmaceuticals scores higher on the StockData Score (17 against 8 for Insmed), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ACAD | INSM |
|---|---|---|
| Size and price | ||
| Market cap | $3.2B | $26.6B |
| Share price | $18.75 | $121.16 |
| Change, 1 year | −22.3% | −37.7% |
| Change, 5 years | −2.1% | 298% |
| Beta (5Y) | 0.78 | 0.76 |
| Employees | 798 | 1,664 |
| StockData Score | ||
| Total score | 17 (better) | 8 |
| Valuation score | 5 (better) | 0 |
| Growth score | 2 | 3 (better) |
| Performance score | 4 (better) | 2 |
| Health score | 6 (better) | 3 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 8.9× | – |
| P/S | 2.7× (better) | 17.5× |
| P/B | 2.3× (better) | 36.6× |
| EV/EBITDA | 18.4× | – |
| P/FCF | 39.4× | – |
| FCF yield | 2.5% (better) | −2.4% |
| Fair value | $31.63 | $60.58 |
| Margin of safety | 40.7% (better) | −100% |
| Growth | ||
| Revenue growth (TTM) | 14.8% | 240% (better) |
| Revenue growth, 5Y average | 19.4% | 29.8% (better) |
| Net income growth (TTM) | 38.7% | – |
| EPS growth (TTM) | 35.5% | – |
| Profitability | ||
| Gross margin | 90.5% (better) | 84.4% |
| Operating margin | 10.2% (better) | −37.1% |
| Net margin | 30.1% (better) | −39.9% |
| FCF margin | 6.8% (better) | −41.3% |
| Return on equity | 31.4% (better) | −72.5% |
| Return on invested capital | 50.8% | – |
| Financial health | ||
| Debt / equity | 0.00 | 0.76 (better) |
| Interest coverage | – | −6.9× |
| Current ratio | 3.82 (better) | 2.86 |
| Altman Z-score | 4.94 | 7.36 (better) |
| Piotroski F-score | 6 (better) | 4 |
| Dividends and buybacks | ||
| Buyback yield | −1.5% | – |
| Shareholder yield | −1.5% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 97.9% | 102% |
| Held by insiders | 27.8% | 0.89% |
| Insider net buying, 12 months | −$2.5M (better) | −$133M |
| Superinvestors holding | – | 1 |
| Short interest, % of float | 6.7% | 6.5% |
Go deeper
- ACAD stock overview
- ACAD income statement
- ACAD valuation and score
- INSM stock overview
- INSM income statement
- INSM valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.